Eluminex Biosciences Closes $40M Series B for Ophthalmic Innovations
China-based ophthalmic biotech Eluminex Biosciences (Suzhou) Ltd has announced the closure of a Series B...
Fineline Cube
RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100...
Junshi Biosciences Reports 2022 Preliminary Earnings with Revenue Decline
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has released its 2022 preliminary earnings estimate, indicating...
Chipscreen Biosciences Licenses First-in-Class BsAb YH008 from Eucure
China-based biopharma Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced a licensing agreement with...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...
Suzhou Porton Biologics Partners with CorrGene for Cell and Gene Therapy
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has announced a strategic...
Sanofi’s Sarclisa Approved for Import in Shenzhen via Greater Bay Area Scheme
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced import approval in Shenzhen via the Greater...
Innovent Biologics Begins Phase I Trial for IBI333 in Neovascular AMD
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first subject dosing in a Phase...
Hybio’s COVID-19 Nasal Spray HY3000 Gets FDA Clinical Trial Approval
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving tacit clinical trial approval from...
Junshi Biosciences’ PCSK9 Inhibitor Ongericimab Meets Phase III Endpoints
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that two randomized, double-blind, placebo-controlled, multi-center...
Oricell Therapeutics Closes $45M Series B1 Round for Cellular Immunotherapy
China-based tumor cellular immunotherapeutics developer Oricell Therapeutics Co., Ltd has announced the closing of a...
CStone’s PD-L1 Inhibitor Sugemalimab Accepted for Review in Gastric Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
Immorna Closes Series A+ and A++ Rounds Near $100M for mRNA Development
Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++...
Sanofi’s VaxigripTetra Approved for Pediatric Influenza Vaccination in China
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced receiving market approval from the National Medical...
Enhertu Approved in China for HER2-Positive Breast Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
Novartis’ Revolade Approved for Severe Aplastic Anemia in China
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving another indication approval from the National...
Kelun-Biotech Files for Hong Kong IPO with Goldman Sachs and CITIC Securities
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its high-end preparation subsidiary,...
Accutar Biotech Begins Phase I Trial for AC0176 in China
New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...
BeiGene’s Tislelizumab Approved for Gastric Tumors in China
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor...
SciClone Partners with Cowell Health to Enhance Cancer Treatment Accessibility
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...